Latest News

Warren Buffett earned the nickname the "Oracle of Omaha" for a reason, but his investing advice was always big-picture oriented.

Starbucks beat fiscal Q4 2026 earnings estimates with 7.7% U.S. comparable sales growth, but revenue missed forecasts as shares dipped and it issued cautious fiscal 2027 guidance.

This is good news for holders, but it still isn't a reason to buy the coin.

CEO Penn reveals pivot to AI-based marketing transformation software driving record results.

Taiwan Semiconductor is set to cash in as long as the build-out continues.

Oracle's long-term outlook suggests that concerns about the health of its balance sheet may be overblown.

Musk's comments suggest that the incredible demand for memory chips is sustainable over the long run.

RevPAR surged 7.2% as luxury demand drove rate growth and pipeline hit record levels.

An early-stage liver disease therapy cut fat by 70% in just 12 weeks, signaling the genetics engine's potential to fuel growth beyond current blockbusters.

The company's net interest margin widened to 3.8% as loan pricing and deposit funding improved, fueling 12% year-over-year growth in core lending profit.

Rockets made SpaceX famous, but its AI business is now its largest driver of growth.

Cost-cutting programs and pricing discipline are shielding margins from commodity inflation, a structural advantage for long-term compounding.

Premium pricing and member engagement drive revenue growth and margin expansion.

FFO grew 5.6% as leasing spreads hit 25% and a $508M acquisition closed.

With major capacity investments behind it, Canadian National can now convert freight growth into pure profit without heavy new spending.

Established office brands are funding the transition to higher-margin tech accessories, a dual-engine strategy that could reshape profitability.

Newer therapies must sustain double-digit growth to offset the impact of Humira's patent cliff, a test that shapes the dividend's long-term safety.

Oklo has fallen hard from its all-time high of $194. Could today's price of $27 imply immense upside?

Data and AI bookings surged 29% as bill rates hit record highs.

Behind a doubling in adjusted EPS sits a more modest picture -- and a dividend streak worth understanding.

New ETF HOID joins humanoid robotics funds KOID and IBOT, which differ in cost, holdings, and performance, as investors weigh long-term growth potential against fees and liquidity.

Consumers don't stop buying vital products during bear markets, which is why healthcare and consumer staples stocks are smart investments.

Operating margins expanded 7.5 points year-over-year, showing how scale translates into earnings power for shareholders.

Investors had to know this day was coming sooner or later.

There's no better teacher than time, although mistakes are a close second.